Cannell & Spears’s Axsome Therapeutics AXSM Stock Holding History

Cannell & Spears’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.2M	Hold	84,154	–	–	0.28%	84
2025 Q4	$15.4M	Buy	84,154 +3	+0%	+$419	0.29%	84
2025 Q3	$10.2M	Hold	84,151	–	–	0.19%	100
2025 Q2	$8.78M	Sell	84,151 -113	-0.1%	-$12K	0.18%	103
2025 Q1	$9.83M	Buy	84,264 +2,177	+3%	+$248K	0.21%	99
2024 Q4	$6.95M	Hold	82,087	–	–	0.14%	114
2024 Q3	$7.38M	Sell	82,087 -5	-0%	-$436	0.15%	114
2024 Q2	$6.61M	Sell	82,092 -638	-0.8%	-$47.2K	0.14%	112
2024 Q1	$6.6M	Buy	+82,730	New	+$6.94M	0.14%	117

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cannell & Spears's AXSM Position: Q1 2026 in Review

Cannell & Spears held its Axsome Therapeutics (AXSM) position steady in Q1 2026 at 84,154 shares worth $14.2M. The position accounts for 0.28% of the portfolio, ranked #84.

Cannell & Spears first reported a position in AXSM in Q1 2024 and has held it in 9 quarters since. The position peaked at $15.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Cannell & Spears held 84,154 shares of Axsome Therapeutics worth $14.2M as of Q1 2026.
Cannell & Spears left its Axsome Therapeutics share count unchanged in Q1 2026.
Axsome Therapeutics made up 0.28% of Cannell & Spears's portfolio in Q1 2026, its #84 holding.
Cannell & Spears first reported a position in Axsome Therapeutics in Q1 2024 and has held it in 9 quarters since.
Cannell & Spears's Axsome Therapeutics position peaked at $15.4M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.